Vascular malformation – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:24:27 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Vascular malformation – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to evaluate the effectiveness of bleomycin sulfate for treating patients with low-flow vascular malformations using electrosclerotherapy. https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-bleomycin-sulfate-injection-for-the-treatment-of-low-flow-vascular-malformations/ Wed, 29 Apr 2026 15:09:51 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-bleomycin-sulfate-injection-for-the-treatment-of-low-flow-vascular-malformations/ This study focuses on the treatment of vascular malformations, which are abnormal growths of blood vessels. Specifically, the research looks at low-flow vascular malformations, a type where blood moves slowly through the affected area. The goal of the study is to determine the effectiveness and feasibility of a treatment method called electrosclerotherapy using the drug bleomycin. This process involves using a specialized technique to deliver the medication directly into the abnormal vessels to help shrink them.

The medication used in this procedure is bleomycin sulfate, which is administered as a solution for injection. During the study, participants undergo the treatment, and their progress is monitored over time. This includes using MRI, a type of imaging that uses magnetic fields to create detailed pictures of the body, to check for changes in the size of the affected area. The follow-up periods occur at three months and twelve months after the procedure to evaluate how well the treatment worked and to monitor any side effects.

]]> Evaluation of Enoxaparin for Prevention of Localized Intravascular Coagulopathy in Children with Slow-Flow Vascular Malformations Undergoing Interventional Procedures https://clinicaltrials.eu/trial/evaluation-of-enoxaparin-for-prevention-of-localized-intravascular-coagulopathy-in-children-with-slow-flow-vascular-malformations-undergoing-interventional-procedures/ Wed, 29 Apr 2026 15:06:19 +0000 https://clinicaltrials.eu/trial/evaluation-of-enoxaparin-for-prevention-of-localized-intravascular-coagulopathy-in-children-with-slow-flow-vascular-malformations-undergoing-interventional-procedures/ This study focuses on slow-flow vascular malformations in children and adolescents. Vascular malformations are abnormalities in blood vessels or lymphatic vessels that are present at birth but may not be visible until later in life. Slow-flow vascular malformations specifically refer to abnormal formations of veins or lymphatic vessels that have slow blood flow through them. During procedures to treat these malformations (such as sclerotherapy, which involves injecting medicine directly into the malformation), patients can develop a condition called localized intravascular coagulopathy, which is an abnormal blood clotting process that occurs within the malformation.

The purpose of this study is to evaluate whether the medication enoxaparin (a type of blood thinner) can effectively and safely prevent this abnormal blood clotting when given before procedures in children with these vascular malformations. Enoxaparin works by interfering with the formation of blood clots. The study will also examine how the treatment affects certain markers of damage to the lining of blood vessels (called endothelial damage markers).

Participants in this study will be children and adolescents aged 0 to 18 years who have been diagnosed with venous malformations or low-flow venous/lymphatic malformations and are scheduled to undergo a procedure such as sclerotherapy, cryoablation (freezing of tissue), or electroporation (using electrical pulses to treat the malformation). Some participants will receive enoxaparin before their procedure, while others will not, and researchers will compare outcomes between these groups.

]]> Study of RLY-2608 for Adults and Children with PIK3CA-Related Overgrowth and Malformations https://clinicaltrials.eu/trial/study-of-rly-2608-for-adults-and-children-with-pik3ca-related-overgrowth-and-malformations/ Wed, 29 Apr 2026 15:04:57 +0000 https://clinicaltrials.eu/trial/study-of-rly-2608-for-adults-and-children-with-pik3ca-related-overgrowth-and-malformations/ This clinical trial is focused on studying a condition known as PIK3CA Related Overgrowth Spectrum and malformations caused by a mutation in the PIK3CA gene. The trial will explore the effects of a new treatment called RLY-2608, which is taken as a capsule. This treatment is designed to target and inhibit a specific protein that is affected by the PIK3CA mutation, potentially helping to manage the symptoms associated with this condition.

The purpose of the study is to determine the best dose of RLY-2608 for different groups of participants and to assess its safety and effectiveness. The study will be conducted in several parts. Initially, participants will receive RLY-2608 to find the most suitable dose and to monitor any side effects. In a later part of the study, the effectiveness of RLY-2608 will be compared to a placebo to see how well it works in reducing the size of the overgrowths or malformations.

Participants in the study will be monitored over a period of time to observe any changes in their condition and to ensure their safety. The study aims to provide valuable information on how RLY-2608 can be used to treat individuals with conditions driven by the PIK3CA mutation, potentially leading to improved treatment options in the future.

]]>